Left Ventricular Thrombus Registry
- Conditions
- Left Ventricular Thrombus
- Registration Number
- NCT06963567
- Lead Sponsor
- Queen Mary University of London
- Brief Summary
Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber.
Having a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis.
A sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1500
- Patients with LV thrombus or;
- Patients at risk for developing LV thrombus (e.g severe LV dysfunction, LV aneurysm, MI.
- Age < 18 years
- Unable to consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite Result From baseline to final 12 month follow up (+/- 2 months) To measure the composite result of major bleeding (BARC \>3), stroke and systemic embolisation, and all-cause mortality
- Secondary Outcome Measures
Name Time Method CMR prediction of thrombus From baseline to 6 month follow up (+/- 3 months) To assess CMR based risk prediction model of recurrence of LV thrombus
Blood Test From baseline to 6 month follow up (+/- 3 months) To assess blood test variables in the persistence or recurrence of LV thrombus
Quality of Life Questionnaire From baseline to final 12 month follow up (+/- 2 months) Participants quality of life (QoL) will be measured using European Quality of Life-5 Dimensions - 5 levels (EQ-5D-5L) questionnaire at baseline and 12 months
Trial Locations
- Locations (1)
St Bartholomew's Hospital
🇬🇧London, United Kingdom